Evaluation of [18F]AlF-NOTA-PCP2 PET/CT for PD-L1 Detection in Malignant Tumors (PD-L1-PET)

March 25, 2025 updated by: Man Hu

Evaluation of the Value of [18F]AlF-NOTA-PCP2 PET/CT for PD-L1 Detection in Malignant Tumors

This phase I/II clinical trial evaluates the safety, efficacy, and prognostic potential of [18F]AlF-NOTA-PCP2 PET/CT imaging in assessing PD-L1 expression in malignant tumors, including glioblastoma, head and neck squamous cell carcinoma, non-small cell lung cancer, and esophageal cancer. The primary aim is to establish the correlation between [18F]AlF-NOTA-PCP2 uptake and PD-L1 expression in tumor tissues, while secondary objectives include evaluating its role in predicting clinical outcomes such as progression-free survival (PFS) and overall survival (OS). By providing a non-invasive, quantitative, and reproducible method for assessing PD-L1, this study aims to refine patient stratification and improve the precision of immunotherapy decision-making.

Study Overview

Status

Enrolling by invitation

Conditions

Intervention / Treatment

Detailed Description

This phase I/II clinical trial is designed to explore the utility of [18F]AlF-NOTA-PCP2 PET/CT in evaluating PD-L1 expression and its prognostic implications in patients with malignant tumors (glioblastoma, head and neck squamous cell carcinoma, non-small cell lung cancer, and esophageal cancer). The study involves at least 20 patients (5 per tumor type) who will undergo a pre-treatment PET/CT scan following an intravenous injection of [18F]AlF-NOTA-PCP2. The primary endpoints include the safety of the imaging protocol and the correlation between [18F]AlF-NOTA-PCP2 uptake (SUV values) and PD-L1 expression determined through immunohistochemistry (IHC). Secondary endpoints explore the dynamic changes in SUV values in patients undergoing multiple scans and their relationship with clinical outcomes.

Scientific and Technical Rationale:

[18F]AlF-NOTA-PCP2 is a novel radiotracer with high specificity for PD-L1, enabling non-invasive imaging of its expression in vivo. This imaging approach complements traditional immunohistochemical methods by offering whole-body assessment, eliminating the need for repeated biopsies, and providing insights into the tumor microenvironment. This study seeks to validate its application in clinical oncology, bridging molecular imaging with biomarker-guided therapeutic strategies.

Study Methods:

Patients will receive a single intravenous dose of [18F]AlF-NOTA-PCP2 (adjusted for body weight), followed by a whole-body PET/CT scan after one hour. Images will be analyzed independently by two experienced nuclear medicine specialists. Tumor biopsies will be collected to measure PD-L1 expression via IHC, and blood samples will be assessed for circulating and exosomal PD-L1 biomarkers. For patients undergoing multiple scans, changes in radiotracer uptake will be tracked to monitor treatment response.

Data Analysis:

SUV values will be correlated with PD-L1 expression levels, clinical factors (e.g., tumor stage, histology), and patient outcomes (PFS, OS). Statistical analyses, performed using SPSS 29.0, will include primary correlations and secondary evaluations of imaging-based dynamic changes and their relationship with therapeutic efficacy.

Significance:

This trial will provide critical data on the feasibility of [18F]AlF-NOTA-PCP2 PET/CT imaging in clinical oncology. Its potential to stratify patients based on PD-L1 expression and predict therapy response could transform personalized cancer care, optimizing immunotherapy outcomes and minimizing unnecessary treatments.

Timeline:

Patient enrollment is expected to last 12 months, with an additional 3 months of follow-up for data collection and analysis.

Study Type

Interventional

Enrollment (Estimated)

100

Phase

  • Phase 2
  • Phase 1

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • China
    • Shandong
      • Jinan, Shandong, China, 250117
        • Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • Signed informed consent obtained.
  • Age ≥ 18 years, any gender.
  • Pathologically confirmed malignant tumors, including:
  • Glioblastoma
  • Head and neck squamous cell carcinoma
  • Non-small cell lung cancer
  • Esophageal cancer
  • Detectable PD-L1 expression in tumor tissue (based on immunohistochemistry or biopsy).
  • Measurable disease with at least one residual tumor lesion.
  • ECOG performance status of 0-1.
  • No contraindications to [18F]AlF-NOTA-PCP2 PET/CT imaging.
  • Willing and able to comply with study procedures and follow-up visits.

Exclusion Criteria:

  • Participation in another interventional clinical trial.
  • Failure to recover from toxic effects or complications of prior interventions (≤ grade 1 or baseline levels, excluding fatigue or hair loss).
  • Pregnant or breastfeeding women.
  • Severe or uncontrolled systemic diseases, including:
  • Major, symptomatic arrhythmias or significant ECG abnormalities (e.g., complete left bundle branch block, second-degree or higher heart block, or ventricular arrhythmias).
  • Unstable angina or congestive heart failure (NYHA class ≥ 2).
  • Any arterial thrombotic or embolic events within 6 months before enrollment (e.g., myocardial infarction, cerebrovascular accident, transient ischemic attack).
  • Active or uncontrolled infections requiring systemic treatment.
  • Severe psychiatric disorders affecting study participation.
  • Any medical history, laboratory abnormality, or condition that may:
  • Interfere with study results.
  • Affect patient participation.
  • Pose an unacceptable risk as determined by the investigator.
  • Women of childbearing potential without a negative pregnancy test prior to study entry.
  • Known allergy or hypersensitivity to [18F]AlF-NOTA-PCP2 or any component of the radiopharmaceutical.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Diagnostic
  • Allocation: N/A
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: [18F]AlF-NOTA-PCP2 PET/CT Imaging for PD-L1 Expression in Malignant Tumors
This arm involves the administration of [18F]AlF-NOTA-PCP2 via intravenous injection followed by whole-body PET/CT imaging one hour later. The objective is to assess the uptake of [18F]AlF-NOTA-PCP2 in malignant tumors and correlate it with PD-L1 expression. This imaging technique is used to evaluate PD-L1 expression in glioblastoma, head and neck squamous cell carcinoma, non-small cell lung cancer, and esophageal cancer patients before treatment, providing a non-invasive, repeatable, and comprehensive approach to guide immunotherapy decisions.
Diagnostic test: PET/CT （[18F]AlF-NOTA-PCP2）
This intervention involves the use of [18F]AlF-NOTA-PCP2, a radiopharmaceutical agent specifically designed for PET/CT imaging. Patients will receive an intravenous injection of [18F]AlF-NOTA-PCP2, followed by whole-body PET/CT scanning one hour later. The primary purpose of this intervention is to assess PD-L1 expression in malignant tumors, including glioblastoma, head and neck squamous cell carcinoma, non-small cell lung cancer, and esophageal cancer, before the initiation of treatment. This imaging technique offers a non-invasive, repeatable, and comprehensive method to monitor PD-L1 status, in contrast to traditional tissue biopsy, which is invasive and limited to a single time point.
Diagnostic test: [18F]AlF-NOTA-PCP2 PET/CT Imaging for PD-L1 Expression in Malignant Tumors
This intervention involves the use of [18F]AlF-NOTA-PCP2, a radiopharmaceutical agent specifically designed for PET/CT imaging. Patients will receive an intravenous injection of [18F]AlF-NOTA-PCP2, followed by whole-body PET/CT scanning one hour later. The primary purpose of this intervention is to assess PD-L1 expression in malignant tumors, including glioblastoma, head and neck squamous cell carcinoma, non-small cell lung cancer, and esophageal cancer, before the initiation of treatment. This imaging technique offers a non-invasive, repeatable, and comprehensive method to monitor PD-L1 status, in contrast to traditional tissue biopsy, which is invasive and limited to a single time point.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Assessment of [18F]AlF-NOTA-PCP2 PET/CT imaging for PD-L1 expression in malignant tumors
Time Frame: Pre-treatment imaging, within 1-7 days before treatment initiation.
This outcome measure will assess the safety and efficacy of [18F]AlF-NOTA-PCP2 PET/CT in detecting PD-L1 expression in malignant tumors (glioblastoma, head and neck squamous cell carcinoma, non-small cell lung cancer, and esophageal cancer). This will include evaluating the correlation between [18F]AlF-NOTA-PCP2 uptake and PD-L1 expression as determined by immunohistochemistry (IHC).
Pre-treatment imaging, within 1-7 days before treatment initiation.

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
[18F]AlF-NOTA-PCP2 PET/CT imaging as a prognostic biomarker in malignant tumors
Time Frame: Up to 1 year of follow-up for clinical outcomes (PFS, OS).
This outcome will evaluate the prognostic value of [18F]AlF-NOTA-PCP2 PET/CT imaging in predicting clinical outcomes, including progression-free survival (PFS) and overall survival (OS), based on tumor PD-L1 expression.
Up to 1 year of follow-up for clinical outcomes (PFS, OS).

Other Outcome Measures

Outcome Measure
Measure Description
Time Frame
Correlation of circulating PD-L1 and exosomal PD-L1 with [18F]AlF-NOTA-PCP2 PET/CT imaging
Time Frame: Pre-treatment, and at follow-up visits (up to 1 year).
This exploratory outcome measure will investigate the correlation between circulating PD-L1 levels, exosomal PD-L1, and [18F]AlF-NOTA-PCP2 PET/CT imaging for assessing PD-L1 expression in tumors.
Pre-treatment, and at follow-up visits (up to 1 year).

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Man Hu

Investigators

  • Study Chair: Man Hu, Dr., Shandong Cancer Hospital and Institute Shandong First Medical University and Shandong Academy of Medical Sciences: Shandong Cancer Hospital and Institute

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

March 30, 2024

Primary Completion (Estimated)

October 31, 2025

Study Completion (Estimated)

October 31, 2026

Study Registration Dates

First Submitted

November 13, 2024

First Submitted That Met QC Criteria

November 13, 2024

First Posted (Actual)

November 15, 2024

Study Record Updates

Last Update Posted (Actual)

March 30, 2025

Last Update Submitted That Met QC Criteria

March 25, 2025

Last Verified

November 1, 2024

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • ShandongCHI202410074
  • KY-2024-136 (Other Identifier: Shandong Cancer Hospital and Institute Shandong First Medical University and Shandong Academy of Medical Sciences: Shan)

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

YES

IPD Plan Description

We plan to share individual participant data (IPD) from this clinical trial, including the following types of data:

Data to be Shared:

Demographic Data: Age, sex, and other basic demographic information. Clinical Data: Diagnosis, treatment regimens, disease stage, and clinical outcomes.

Imaging Data: PET/CT scan images and associated quantitative data (e.g., SUV values) related to [18F]AlF-NOTA-PCP2 uptake.

Biomarker Data: Results from PD-L1 expression assays, including tissue sample data and blood biomarkers.

Adverse Event Data: Adverse event reports, including the type, severity, and outcome as graded by the NCI CTCAE.

How the Data Will Be Shared:

The IPD will be shared via a secure, password-protected database or a data-sharing platform. Access will be granted to qualified researchers upon submission of a data request proposal.

The sharing process will include a data use agreement (DUA) that outlines the terms of use, data protection protocols, and the research purposes for which

IPD Sharing Time Frame

Start Date: The IPD and supporting information will be available starting after the completion of the primary analysis and publication of study results, which is expected to be by October 2025.

End Date: The IPD and supporting information will be available for a period of 5 years following study completion, until October 2030.

IPD Sharing Access Criteria

Who will have access: Access to the individual participant data (IPD) and supporting information will be available to qualified researchers, healthcare professionals, and institutions involved in academic research or related scientific studies. This may include those interested in replicating the study results, conducting further analyses, or exploring the data for new scientific questions.

What will be accessible: Researchers will have access to:

The full individual participant data (IPD), including anonymized data related to clinical outcomes, imaging results (e.g., PET/CT scans), and laboratory tests.

Supporting documents, such as the study protocol, statistical analysis plan (SAP), informed consent form (ICF), and the clinical study report (CSR), which provide details on the methodology, analysis approach, and results.

How to access: Researchers can request access to the IPD and supporting information through the official study contact, Dr. Man Hu (contact: mhu@sdfmu.edu.cn). Upo

IPD Sharing Supporting Information Type

  • STUDY_PROTOCOL
  • SAP
  • ICF
  • ANALYTIC_CODE
  • CSR

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Esophageal Cancer

Clinical Trials on PET/CT （[18F]AlF-NOTA-PCP2）

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Georgia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe